10x Genomics announced a multi-year collaboration with Lausanne University Hospital to use single-cell and spatial technologies to discover tumor biomarkers tied to treatment response and resistance across advanced solid cancers. The work will use 10x’s Flex APEX and Xenium platforms, with an expansion plan toward the company’s Atera platform. The collaboration will analyze tumor samples from patients evaluated by clinical molecular tumor boards, integrating multimodal data with clinical outcome records. Target solid cancer types include non-small cell lung cancer, breast cancer, bladder cancer, and melanoma. The stated goal is to identify clinically actionable biomarkers that improve patient selection and support future diagnostic integration into routine tumor board decision-making.